Biogen (BIIB) Q2 2025 Earnings Transcript

Biogen reported Q2 revenue of $2.8 billion, up 7% year over year, with non-GAAP diluted EPS of $5.25 and adjusted EPS of $5.73 excluding IPR&D. Management raised full-year 2025 non-GAAP EPS guidance to $15.50-$16 and said revenue should be approximately flat versus 2024, driven by strong launch products including LEQEMBI, SKYCLARYS, and ZURZUVAE. The company also highlighted pipeline progress in felzartamab and salanersen, while noting headwinds from ex-U.S. MS competition, SPINRAZA shipment timing, and higher interest expense from debt refinancing.

Analysis

BIIB is transitioning from a single-dominant franchise story to a portfolio compounding story, and that matters because the market usually underwrites these turnarounds too conservatively until the mix shift becomes self-sustaining. The key second-order effect is that launch-product growth is now doing more than offsetting MS erosion: it is also creating an operating leverage flywheel, where each incremental dollar of demand matters more because the cost base is being reset and capital is being redeployed into higher-value late-stage assets.

The most underappreciated catalyst is not near-term revenue; it is infrastructure. LEQEMBI’s market expansion is being driven by diagnosis and access bottlenecks, which means the upside is increasingly a function of ecosystem maturation rather than just physician preference. If blood-based testing and subcutaneous maintenance reduce friction even modestly, the addressable treated population can expand faster than consensus models imply, while also lowering the operational burden on infusion sites — a setup that could re-rate the entire Alzheimer’s asset, not just the current label.

The bear case is that the first half likely overstates run-rate quality: U.S. MS benefited from transient inventory and gross-to-net tailwinds, while ex-U.S. MS and SPINRAZA face second-half drag. That creates a classic “good headline, soft denominator” risk into the next two quarters, especially if investors anchor on the raised EPS guide and ignore that some of the lift is non-recurring and that incremental interest expense plus planned plant maintenance will bite later in the year. The stock’s durable upside depends on whether launch momentum and pipeline confidence can outrun those timing headwinds.

Contrarian takeaway: consensus may be underestimating how quickly BIIB can become a free-cash-flow compounder again if the launch portfolio keeps scaling and management continues to use R&D spend as a call option rather than a sunk-cost sinkhole. The more interesting trade is not a simple long on “earnings beat,” but a long-duration re-rating on evidence that LEQEMBI adoption, ZURZUVAE persistence, and rare-disease launches are all contributing to a broader multiple expansion story.

Key Decisions for Investors

• Long BIIB into the next 1-3 months on pullbacks, targeting a re-rating toward peers if LEQEMBI access metrics and launch-product growth remain intact; risk is Q3/Q4 deceleration from MS/SPINRAZA timing and inventory unwind.
• Pair trade: long BIIB / short a basket of mature large-cap biotech names with stalled top-line growth over the next 2 quarters; BIIB has a clearer mix-shift catalyst and more visible operating leverage.
• Buy BIIB Jan-2026 call spreads to express upside from subcutaneous LEQEMBI approval and blood-biomarker adoption, while capping premium at risk; catalyst window is end-August through year-end.
• Fade short-term enthusiasm if BIIB rallies sharply on the EPS raise alone; trim or hedge above levels that price in sustained first-half run-rate, because part of the beat is non-recurring and second-half comparisons get harder.
• Monitor STOK as a relative beneficiary only if salanersen Phase III design and timelines de-risk quickly; otherwise keep it as a high-volatility optionality name rather than a core long.